Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression.

Antimicrobial Agents and Chemotherapy
Phillip K PetersonC C Chao

Abstract

Mycobacterium tuberculosis accelerates the progression of human immunodeficiency virus type 1 (HIV-1) infection. The results of this study, which show that thalidomide inhibits the upregulation of HIV-1 expression in U1 cells stimulated with mycobacterial lipoarabinomannans, support the rationale behind conducting controlled trials of this immunodeficiency agent with patients dually infected with HIV-1 and M. tuberculosis.

References

Feb 1, 1992·AIDS Research and Human Retroviruses·G Poli, A S Fauci
Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
Oct 1, 1988·The Journal of Infectious Diseases·B IsakssonP Putkonen
Oct 1, 1994·Antimicrobial Agents and Chemotherapy·P K PetersonC C Chao
Feb 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D L PatersonR J Kemp
Jun 1, 1995·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·P KissingerW Brandon
Jan 1, 1995·American Journal of Respiratory and Critical Care Medicine·C WhalenJ Ellner
Apr 1, 1995·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·D J MartinK Keddy
Mar 30, 1994·Biochemical and Biophysical Research Communications·S GollapudiS Gupta
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·S MakonkawkeyoonG Kaplan

❮ Previous
Next ❯

Citations

Feb 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N P JuffermansT van Der Poll
Oct 19, 2004·Clinical Microbiology Reviews·R Bryan RockPhillip K Peterson
Oct 18, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·C MeierhoferC J Wiedermann
Jul 5, 2005·Expert Opinion on Investigational Drugs·C Grassi
Jan 1, 1997·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·G VanhamJ J Ellner
Mar 6, 2012·Journal of Neuroscience Methods·Fabíola C R ZucchiOsvaldo M Takayanagui

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.